You might also like
ElectroCore, Inc. (ECOR) is a company focused on the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapy. It offers innovative solutions for treating various medical conditions and enhancing wellness through its proprietary technology. ECOR sells both prescription and nonprescription products designed to provide therapeutic benefits and improve human performance.
- Prescription gammaCore Medical Devices - Offers handheld, personal-use medical devices for treating conditions such as migraines and cluster headaches, primarily sold through VA/DoD channels.
- Truvaga - Provides direct-to-consumer general wellness products aimed at stress relief, relaxation, sleep improvement, and mental acuity.
- TAC-STIM - Targets human performance enhancement, particularly for military personnel, with nonprescription products that do not require a prescription.
-
The growth in prescription gammaCore sales has slowed since the number of active sales groups has remained constant since July 2024 . What specific strategies are in place to reaccelerate this growth, and do you plan to expand your sales force to achieve this?
-
Given that Truvaga sales surged during the holiday season but have normalized in the first quarter of 2025 , how sustainable is the growth in the Truvaga channel, and what strategies are you implementing to drive consistent sales throughout the year?
-
With the acquisition of NeuroMetrix and the distribution agreement with Spark Biomedical, how do you expect these additions to affect gross margins, considering that these products may have lower margins than your existing products ?
-
You mentioned possible disruptions in the VA hospital system due to macro forces and personnel reductions . How significant is this risk to your business, given that the VA is your largest customer, and what measures are you taking to mitigate potential impacts?
-
Regarding your capital adequacy, you indicated that you have plenty of runway but also acknowledged opportunities for faster growth if you made bigger investments. Do you anticipate needing to raise additional capital in the near to mid-term to fund expansion, and how would that affect shareholder value?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Allergan plc | Many of our current and potential primary headache competitors are publicly traded, or are divisions of publicly traded, major pharmaceutical and medical device companies that have substantially greater financial, technical, sales and marketing resources than we do. We will face steep competition from this company, among other established and potential competitors that may be better capitalized and have a history of commercializing products around the world. |
Many of our current and potential primary headache competitors are publicly traded, or are divisions of publicly traded, major pharmaceutical and medical device companies that have substantially greater financial, technical, sales and marketing resources than we do. We will face steep competition from this company, among other established and potential competitors that may be better capitalized and have a history of commercializing products around the world. | |
H. Lundbeck A/S | Many of our current and potential primary headache competitors are publicly traded, or are divisions of publicly traded, major pharmaceutical and medical device companies that have substantially greater financial, technical, sales and marketing resources than we do. We will face steep competition from this company, among other established and potential competitors that may be better capitalized and have a history of commercializing products around the world. |
Novartis International AG | Many of our current and potential primary headache competitors are publicly traded, or are divisions of publicly traded, major pharmaceutical and medical device companies that have substantially greater financial, technical, sales and marketing resources than we do. We will face steep competition from this company, among other established and potential competitors that may be better capitalized and have a history of commercializing products around the world. |
Many of our current and potential primary headache competitors are publicly traded, or are divisions of publicly traded, major pharmaceutical and medical device companies that have substantially greater financial, technical, sales and marketing resources than we do. We will face steep competition from this company, among other established and potential competitors that may be better capitalized and have a history of commercializing products around the world. | |
Many of our current and potential primary headache competitors are publicly traded, or are divisions of publicly traded, major pharmaceutical and medical device companies that have substantially greater financial, technical, sales and marketing resources than we do. We will face steep competition from this company, among other established and potential competitors that may be better capitalized and have a history of commercializing products around the world. | |
Many of our current and potential primary headache competitors are publicly traded, or are divisions of publicly traded, major pharmaceutical and medical device companies that have substantially greater financial, technical, sales and marketing resources than we do. We will face steep competition from this company, among other established and potential competitors that may be better capitalized and have a history of commercializing products around the world. | |
Cefaly | Several neuromodulation devices are approved for the treatment and/or prevention of migraine, including this device, which has been granted an OTC clearance allowing it to be sold without a prescription, and the impact of this clearance on the competitive landscape remains to be seen. |
Nerivio | There are several neuromodulation devices that have been marketed for the treatment of migraine, including this device, as well as other neuromodulation devices that may be marketed for use in treating pain associated with primary headache. |
Savi Dual | There are several neuromodulation devices that have been marketed for the treatment of migraine, including this device, as well as other neuromodulation devices that may be marketed for use in treating pain associated with primary headache. |
Some of the world’s largest technology companies that have not historically operated in the general wellness and/or medical device spaces have notably developed or may in the future develop products and technologies that may compete with our current or future products and technologies. Such companies have substantially greater capital, research and development, and sales resources than we have. | |
Some of the world’s largest technology companies that have not historically operated in the general wellness and/or medical device spaces have notably developed or may in the future develop products and technologies that may compete with our current or future products and technologies. Such companies have substantially greater capital, research and development, and sales resources than we have. | |
Some of the world’s largest technology companies that have not historically operated in the general wellness and/or medical device spaces have notably developed or may in the future develop products and technologies that may compete with our current or future products and technologies. Such companies have substantially greater capital, research and development, and sales resources than we have. | |
Samsung Electronics Co., Ltd. | Some of the world’s largest technology companies that have not historically operated in the general wellness and/or medical device spaces have notably developed or may in the future develop products and technologies that may compete with our current or future products and technologies. Such companies have substantially greater capital, research and development, and sales resources than we have. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
NeuroMetrix, Inc. (NURO) | 2024 | ElectroCore entered a definitive agreement in 2024 to acquire NURO, including its Quell® platform, a wearable neuromodulation device for fibromyalgia and chronic lower-extremity pain, while excluding the DPNCheck® technology which will be divested prior to closing. The deal structure involves NURO shareholders receiving cash equivalent to NURO’s net cash balance (after deductions) plus one contingent value right (CVR) per share with performance-linked royalty provisions, and the acquisition is strategically aimed at expanding electroCore’s portfolio of non-invasive therapies and increasing its market reach, subject to customary conditions and approval requirements. |
Recent press releases and 8-K filings for ECOR.
- Q1 2025 net sales reached $6.7 million, a 23% increase over Q1 2024, with gross margins at 85%; performance driven by higher Rx gammaCore sales, international growth, and Truvaga traction .
- Closed the acquisition of NeuroMetrix, Inc., expanding its portfolio with the Quell product line and bolstering its non-invasive bioelectronic therapies for fibromyalgia and chronic pain in VA and U.K. channels .
- Restructured the sales team and increased media spend to accelerate growth toward achieving cash neutrality with an expected quarterly revenue target of around $9 million .
- GAAP net loss widened to $3.9 million, while adjusted EBITDA net loss improved to $3.1 million in Q1 2025 .
- Full-year 2025 guidance projects approximately $30.0 million in total revenue, with expected contributions from NeuroMetrix by year-end .
- Acquisition Completed: electroCore, Inc. has finalized its merger with NeuroMetrix, converting each NURO share into $4.49 cash per share plus one contingent value right, making NeuroMetrix an indirect wholly-owned subsidiary.
- Portfolio Expansion: The acquisition adds NeuroMetrix’s Quell Fibromyalgia Solution to electroCore’s portfolio, broadening its range in non-invasive bioelectronic therapies and targeting growth in chronic pain and wellness markets.